Durect corporation to present at the h.c. wainwright global investment conference

Cupertino, calif. , sept. 4, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the h.c.

DRRX Ratings Summary

DRRX Quant Ranking